NCT01802359

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of mirodenafil in participants with erectile dysfunction.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
379

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2011

Shorter than P25 for all trials

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 7, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2012

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 1, 2013

Completed
Last Updated

June 22, 2017

Status Verified

June 1, 2017

Enrollment Period

7 months

First QC Date

February 28, 2013

Last Update Submit

June 21, 2017

Conditions

Keywords

Erectile dysfunctionMirodenafilBravonto

Outcome Measures

Primary Outcomes (1)

  • Number of participants with adverse events

    Up to 4 weeks

Secondary Outcomes (4)

  • International Index of Erectile Function

    Baseline (Week 0), Week 4, Week 8, and Week 12

  • Sexual Encounter Profile

    Baseline (Week 0), Week 4, Week 8, and Week 12

  • Global assessment Questionnaire

    Baseline (Week 0), Week 4, Week 8, and Week 12

  • Number of participants with adverse events

    Up to 12 weeks

Study Arms (1)

Mirodenafil

Drug: No intervention

Interventions

This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.

Mirodenafil

Eligibility Criteria

Age19 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants diagnosed with erectile dysfunction and prescribed mirodenafil on demand.

You may qualify if:

  • Participants diagnosed with erectile dysfunction
  • Participants prescribed mirodenafil on demand

You may not qualify if:

  • \- Participants who have administered mirodenafil for other than an approved indication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Erectile Dysfunction

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Study Officials

  • Janssen Korea, Ltd., Korea Clinical Trial

    Janssen Korea, Ltd., Korea

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2013

First Posted

March 1, 2013

Study Start

November 7, 2011

Primary Completion

May 31, 2012

Study Completion

May 31, 2012

Last Updated

June 22, 2017

Record last verified: 2017-06